Almirall (0O9B) AI Stock Analysis

Almirall

(LSE:0O9B)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved Revenue and ProfitabilityThe sharp TTM revenue acceleration alongside positive profitability indicates stronger commercial performance across Almirall’s branded pharmaceutical portfolio. If sustained, improved scale and healthy gross margins can support reinvestment in dermatology products, geographic reach, and lifecycle management.

Negative Factors

Historical Earnings VolatilityThe return to profitability is encouraging, but the multi-year swings in net results make current earnings power less predictable. Continued volatility could complicate planning, reduce confidence in margin durability, and limit the consistency of funds available for investment in the product portfolio.

Almirall (0O9B) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 2.31B
Dividend Yield: 1.73%
Average Volume (3M): 26.96K
Price to Earnings (P/E): 32.0
Beta (1Y): 0.92
Revenue Growth: 9.67%
EPS Growth: 174.00%
Country: UK
Employees: 2,097
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Almirall Business Overview & Revenue Model

Company Description

Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its...

Almirall Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0O9B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ES:CBAV	85Outperform	EUR 867.34M	19.00	41.91%	2.95%	10.89%	17.12%
ES:FAE	61Neutral	EUR 1.50B	11.10	18.19%	2.65%	31.88%	-20.09%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ES:RJF	52Neutral	EUR 212.43M	30.46	3.14%	0.75%	-0.42%	4.56%

* General Sector Average

Performance Comparison

GB:0O9B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0O9B	Almirall SA	10.62	-1.38	-11.51%
ES:CBAV	Clinica Baviera	53.20	12.09	29.42%
ES:FAE	Faes Farma	4.83	0.50	11.59%
ES:RJF	LABORATORIO REIG JOFRE	2.58	-0.29	-10.01%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Almirall AI Stock Analysis